Narendranath Epperla, MD, MS

Videos

Promising Prognostic Value of Diagnosis to Treatment Interval Among Patients With Newly Diagnosed Mantle Cell Lymphoma

08/17/2023

Narendranath Epperla, MD, MS, shares findings assessing the potential significance of DTI for predicting outcomes for patients with newly diagnosed MCL.

Narendranath Epperla, MD, MS,...

08/17/2023

Oncology

Videos

Exploring the Role of FGFR1 as a Therapeutic Target Among Patients With MCL

09/22/2023

Narendranath Epperla , MD, MS;

Narendranath Epperla, MD, MS, discusses the current research on fibroblast growth factor receptor-1 as an up-and-coming and viable therapeutic target for patients with mantle cell lymphoma.

Narendranath Epperla, MD, MS,...

09/22/2023

Oncology

Conference Coverage

Assessing the Optimal Ki-67 Cut-Off for Outcome Prediction Among Patients With Newly Diagnosed Mantle Cell Lymphoma

12/10/2023

Narendranath Epperla , MD, MS;

At the 65th ASH Annual Meeting, Narendranath Epperla, MD, MS, shared insights on an optimal Ki-67 cut-off for patients with newly diagnosed mantle cell lymphoma, which was found to be prognostic for progression-free survival, but not overall...

At the 65th ASH Annual Meeting,...

12/10/2023

Oncology

Conference Coverage

Analyzing Outcomes of Tafasitamab for the Treatment of R/R DLBCL Among Racial and Ethnic Minorities

12/11/2023

Narendranath Epperla , MD, MS;

At the 2023 ASH Annual Meeting, Narendranath Epperla, MD, MS, presented a retrospective cohort study analyzing the patterns and outcomes of treatment with tafasitamab among patients with R/R diffuse large B-cell lymphoma across racial and...

At the 2023 ASH Annual Meeting,...

12/11/2023

Oncology